Evidence map›Paper›PMID 39105751›Full record

ArticleACS nano2024

Discovery of a Peptoid-Based Nanoparticle Platform for Therapeutic mRNA Delivery via Diverse Library Clustering and Structural Parametrization.

Elizabeth R Webster, Nicole E Peck, Juan Diego Echeverri, Shima Gholizadeh, Wei-Lun Tang, Rinette Woo, Anushtha Sharma, Weiqun Liu, Chris S Rae, Adrienne Sallets and 7 more

Abstract read
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Sequence-defined peptoidsChemical science · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Elizabeth R WebsterNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.ORCID 0000-0003-2764-1118
Nicole E PeckNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Juan Diego EcheverriNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.ORCID 0009-0000-3963-3866
Shima GholizadehNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Wei-Lun TangNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Rinette WooNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Anushtha SharmaNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Weiqun LiuNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Chris S RaeNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Adrienne SalletsNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Gowrisudha AdusumilliNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Kannan GunasekaranNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Ole A W HaabethNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Meredith LeongNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Ronald N ZuckermannMolecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States.ORCID 0000-0002-3055-8860
Samuel DeutschNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.
Colin J McKinlayNutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States.ORCID 0009-0005-7867-0244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticle-mediated mRNA delivery has emerged as a promising therapeutic modality, but its growth is still limited by the discovery and optimization of effective and well-tolerated delivery strategies. Lipid nanoparticles containing charged or ionizable lipids are an emerging standard for in vivo mRNA delivery, so creating facile, tunable strategies to synthesize these key lipid-like molecules is essential to advance the field. Here, we generate a library of N-substituted glycine oligomers, peptoids, and undertake a multistage down-selection process to identify lead candidate peptoids as the ionizable component in our Nutshell nanoparticle platform. First, we identify a promising peptoid structural motif by clustering a library of >200 molecules based on predicted physical properties and evaluate members of each cluster for reporter gene expression in vivo. Then, the lead peptoid motif is optimized using design of experiments methodology to explore variations on the charged and lipophilic portions of the peptoid, facilitating the discovery of trends between structural elements and nanoparticle properties. We further demonstrate that peptoid-based Nutshells leads to expression of therapeutically relevant levels of an anti-respiratory syncytial virus antibody in mice with minimal tolerability concerns or induced immune responses compared to benchmark ionizable lipid, DLin-MC3-DMA. Through this work, we present peptoid-based nanoparticles as a tunable delivery platform that can be optimized toward a range of therapeutic programs.

Indexed as

NanoparticlesPeptoidsRNA, MessengerAnimalsHumansLipidsMiceRespiratory Syncytial VirusesLipidsPeptoidsRNA, Messengerdesign of experimentshigh-throughput screeninglipid nanoparticlemRNA deliverynucleic acid deliverypeptoid

Identifiers

PMID39105751
PMCPMC11342374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.